KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Goodwill: 2015-2019

Historic Goodwill for Arbutus Biopharma (ABUS) over the last 4 years, with Jun 2019 value amounting to $22.5 million.

  • Arbutus Biopharma's Goodwill changed negligibly% to $22.5 million in Q2 2019 from the same period last year, while for Jun 2019 it was $22.5 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $22.5 million for FY2018, which is 7.77% down from last year.
  • According to the latest figures from Q2 2019, Arbutus Biopharma's Goodwill is $22.5 million, which was down 0.00% from $22.5 million recorded in Q1 2019.
  • Over the past 5 years, Arbutus Biopharma's Goodwill peaked at $162.5 million during Q4 2015, and registered a low of $22.5 million during Q2 2018.
  • Over the past 3 years, Arbutus Biopharma's median Goodwill value was $23.4 million (recorded in 2017), while the average stood at $23.4 million.
  • Within the past 5 years, the most significant YoY rise in Arbutus Biopharma's Goodwill was 4.27% (2016), while the steepest drop was 85.01% (2016).
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Goodwill stood at $162.5 million in 2015, then plummeted by 85.01% to $24.4 million in 2016, then remained steady at $24.4 million in 2017, then decreased by 7.77% to $22.5 million in 2018, then remained steady at $22.5 million in 2019.
  • Its Goodwill stands at $22.5 million for Q2 2019, versus $22.5 million for Q1 2019 and $22.5 million for Q4 2018.